Literature DB >> 25639954

Protein kinase A directly phosphorylates metabotropic glutamate receptor 5 to modulate its function.

Ken Uematsu1, Myriam Heiman, Marina Zelenina, Júlio Padovan, Brian T Chait, Anita Aperia, Akinori Nishi, Paul Greengard.   

Abstract

Metabotropic glutamate receptor 5 (mGluR5) regulates excitatory post-synaptic signaling in the central nervous system (CNS) and is implicated in various CNS disorders. Protein kinase A (PKA) signaling is known to play a critical role in neuropsychiatric disorders such as Parkinson's disease, schizophrenia, and addiction. Dopamine signaling is known to modulate the properties of mGluR5 in a cAMP- and PKA-dependent manner, suggesting that mGluR5 may be a direct target for PKA. Our study identifies mGluR5 at Ser870 as a direct substrate for PKA phosphorylation and demonstrates that this phosphorylation plays a critical role in the PKA-mediated modulation of mGluR5 functions such as extracellular signal-regulated kinase phosphorylation and intracellular Ca(2+) oscillations. The identification of the molecular mechanism by which PKA signaling modulates mGluR5-mediated cellular responses contributes to the understanding of the interaction between dopaminergic and glutamatergic neuronal signaling. We identified serine residue 870 (S870) in metabotropic glutamate receptor 5 (mGluR5) as a direct substrate for protein kinase A (PKA). The phosphorylation of this site regulates the ability of mGluR5 to induce extracellular signal-regulated kinase (ERK) phosphorylation and intracellular Ca(2+) oscillations. This study provides a direct molecular mechanism by which PKA signaling interacts with glutamate neurotransmission.
© 2015 International Society for Neurochemistry.

Entities:  

Keywords:  Ca2+ oscillations; extracellular signal-regulated kinase; mGluR5; phosphorylation; protein kinase A

Mesh:

Substances:

Year:  2015        PMID: 25639954      PMCID: PMC4359654          DOI: 10.1111/jnc.13038

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  39 in total

Review 1.  Cognitive effects of Group I metabotropic glutamate receptor ligands in the context of drug addiction.

Authors:  M Foster Olive
Journal:  Eur J Pharmacol       Date:  2010-04-02       Impact factor: 4.432

Review 2.  Pharmacological and functional characteristics of metabotropic excitatory amino acid receptors.

Authors:  D Schoepp; J Bockaert; F Sladeczek
Journal:  Trends Pharmacol Sci       Date:  1990-12       Impact factor: 14.819

Review 3.  The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system.

Authors:  D T Monaghan; R J Bridges; C W Cotman
Journal:  Annu Rev Pharmacol Toxicol       Date:  1989       Impact factor: 13.820

4.  Modulation of the neuronal dopamine transporter activity by the metabotropic glutamate receptor mGluR5 in rat striatal synaptosomes through phosphorylation mediated processes.

Authors:  G Page; M Peeters; M Najimi; J M Maloteaux; E Hermans
Journal:  J Neurochem       Date:  2001-03       Impact factor: 5.372

5.  Purification and characterization of Ca2+/calmodulin-dependent protein kinase I from bovine brain.

Authors:  A C Nairn; P Greengard
Journal:  J Biol Chem       Date:  1987-05-25       Impact factor: 5.157

Review 6.  Fragile X Syndrome and Alzheimer's Disease: Another story about APP and beta-amyloid.

Authors:  J S Malter; B C Ray; P R Westmark; C J Westmark
Journal:  Curr Alzheimer Res       Date:  2010-05       Impact factor: 3.498

Review 7.  Metabotropic glutamate receptors: physiology, pharmacology, and disease.

Authors:  Colleen M Niswender; P Jeffrey Conn
Journal:  Annu Rev Pharmacol Toxicol       Date:  2010       Impact factor: 13.820

Review 8.  Glutamate receptors as therapeutic targets for Parkinson's disease.

Authors:  Kari A Johnson; P Jeffrey Conn; Colleen M Niswender
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

9.  Phosphorylation of the homer-binding domain of group I metabotropic glutamate receptors by cyclin-dependent kinase 5.

Authors:  Lianna R Orlando; Ramses Ayala; Lauren R Kett; Allison A Curley; Jay Duffner; D Cristopher Bragg; Li-Huei Tsai; Anthone W Dunah; Anne B Young
Journal:  J Neurochem       Date:  2009-04-30       Impact factor: 5.372

10.  A family of metabotropic glutamate receptors.

Authors:  Y Tanabe; M Masu; T Ishii; R Shigemoto; S Nakanishi
Journal:  Neuron       Date:  1992-01       Impact factor: 17.173

View more
  10 in total

Review 1.  Metabotropic glutamate receptor subtype 5: molecular pharmacology, allosteric modulation and stimulus bias.

Authors:  K Sengmany; K J Gregory
Journal:  Br J Pharmacol       Date:  2015-11-11       Impact factor: 8.739

2.  Phosphorylation of group I metabotropic glutamate receptors in drug addiction and translational research.

Authors:  Li-Min Mao; Qiang Wang
Journal:  J Transl Neurosci (Beijing)       Date:  2016-09

3.  Regulation of Metabotropic Glutamate Receptor Internalization and Synaptic AMPA Receptor Endocytosis by the Postsynaptic Protein Norbin.

Authors:  Prachi Ojha; Subhajit Pal; Samarjit Bhattacharyya
Journal:  J Neurosci       Date:  2021-12-14       Impact factor: 6.709

4.  Activated CaMKIIα Binds to the mGlu5 Metabotropic Glutamate Receptor and Modulates Calcium Mobilization.

Authors:  Christian R Marks; Brian C Shonesy; Xiaohan Wang; Jason R Stephenson; Colleen M Niswender; Roger J Colbran
Journal:  Mol Pharmacol       Date:  2018-10-03       Impact factor: 4.436

Review 5.  Posttranslational Modifications Regulate the Postsynaptic Localization of PSD-95.

Authors:  Daniela Vallejo; Juan F Codocedo; Nibaldo C Inestrosa
Journal:  Mol Neurobiol       Date:  2016-02-16       Impact factor: 5.590

Review 6.  Metabotropic glutamate receptor trafficking.

Authors:  Young Ho Suh; Kai Chang; Katherine W Roche
Journal:  Mol Cell Neurosci       Date:  2018-03-29       Impact factor: 4.314

7.  Metabotropic glutamate receptor 5 inhibits α-synuclein-induced microglia inflammation to protect from neurotoxicity in Parkinson's disease.

Authors:  Ya-Nan Zhang; Jing-Kai Fan; Li Gu; Hui-Min Yang; Shu-Qin Zhan; Hong Zhang
Journal:  J Neuroinflammation       Date:  2021-01-18       Impact factor: 8.322

8.  Monoallelic and bi-allelic variants in NCDN cause neurodevelopmental delay, intellectual disability, and epilepsy.

Authors:  Ambrin Fatima; Jan Hoeber; Jens Schuster; Eriko Koshimizu; Carolina Maya-Gonzalez; Boris Keren; Cyril Mignot; Talia Akram; Zafar Ali; Satoko Miyatake; Junpei Tanigawa; Takayoshi Koike; Mitsuhiro Kato; Yoshiko Murakami; Uzma Abdullah; Muhammad Akhtar Ali; Rein Fadoul; Loora Laan; Casimiro Castillejo-López; Maarika Liik; Zhe Jin; Bryndis Birnir; Naomichi Matsumoto; Shahid M Baig; Joakim Klar; Niklas Dahl
Journal:  Am J Hum Genet       Date:  2021-03-11       Impact factor: 11.025

Review 9.  Chronic stress-induced synaptic changes to corticotropin-releasing factor-signaling in the bed nucleus of the stria terminalis.

Authors:  Isabella Maita; Troy A Roepke; Benjamin A Samuels
Journal:  Front Behav Neurosci       Date:  2022-08-02       Impact factor: 3.617

Review 10.  Insights on the Functional Interaction between Group 1 Metabotropic Glutamate Receptors (mGluRI) and ErbB Receptors.

Authors:  Ada Ledonne; Nicola B Mercuri
Journal:  Int J Mol Sci       Date:  2020-10-24       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.